drugset / Trial / NCT00751153

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

NCT00751153

Phase 4 Unknown 40 enrolled Peter J. Ruane, M.D., Inc.
NaSingle-groupOpen-labelTreatment

Summary

Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and be monitored for viral and immunological response and quality of life.

Timeline

Start
2008-03
Primary completion
2009-10
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 400 mg
Subject Raltegravir Other / unclassified 400 mg